<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039866</url>
  </required_header>
  <id_info>
    <org_study_id>ST-920-LT01</org_study_id>
    <nct_id>NCT05039866</nct_id>
  </id_info>
  <brief_title>Long-Term Follow-up of Subjects Who Were Treated With ST-920</brief_title>
  <official_title>Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and&#xD;
      completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled&#xD;
      subjects will be followed for a total of up to 5 years following ST-920 infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with&#xD;
      ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at&#xD;
      least 52 weeks post-infusion follow-up in their primary protocol will be offered to&#xD;
      participate. Subjects who enroll will be monitored for a total of up to 5 years following&#xD;
      ST-920 infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate long-term safety of ST-920</measure>
    <time_frame>4 years</time_frame>
    <description>To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Fabry Disease</condition>
  <condition>Fabry Disease, Cardiac Variant</condition>
  <arm_group>
    <arm_group_label>Subjects who received ST-920</arm_group_label>
    <description>Subjects who received ST-920 in clinical study ST-920-201</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ST-920</intervention_name>
    <description>No study drug is administered in this study. Subject who received ST-920 in a previous trial (ST-920-201) will be evaluated in this trial for long-term safety.</description>
    <arm_group_label>Subjects who received ST-920</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects who have received ST-920 in Study Protocol ST-920-201 and who have consented&#xD;
        to participate in this Long Term Follow-up study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who received ST-920 therapy in a separate parent trial (ST-920-201)&#xD;
&#xD;
          -  Subjects who have consented to participate in this LTFU study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -This study has no exclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lysosomal &amp; Rare Disorders Research &amp; Treatment Center (LDRTC)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry Disease</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>ST-920</keyword>
  <keyword>Rare</keyword>
  <keyword>Genetic</keyword>
  <keyword>DNA</keyword>
  <keyword>Sangamo</keyword>
  <keyword>Long Term</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

